Ottawa, March 22, 2023 – Innovative Medicines Canada (IMC) is encouraged by the federal government’s announcement regarding its intentions for $1.5B in previously earmarked funds to support rare disease patients in Canada. Today’s news is a step forward for the 1 in 12 Canadians who suffer from a rare disease, most of whom are children. Bi-lateral work between the federal and provincial and territorial governments, focus on better patient data, and a new stakeholder advisory group are just some of the elements announced today. As the government builds toward and refines a national strategy on drugs for rare diseases, IMC remains committed to working collaboratively to ensure that patients not only get the medicines they need, but that access to these life-changing treatments is timely and efficient.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 49 companies who invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
– 30 –
For further information:
Erin Brophy,
Executive Director
E-mail: media@imc-mnc.ca
